Researchers find ways to improve Kalydeco CF treatment; IntelGenx, RedHill introduce oral 'film' for migraines;

> Vertex's ($VRTX) Kalydeco, the first drug to treat the genetic causes of cystic fibrosis, may be more effective and targeted, researchers at the University of Missouri said. Article

> IntelGenx, along with RedHill Biopharma, submitted an NDA for a migraine treatment to be delivered orally as a thin, dissolving film, releasing the drug Rizatriptan. Release

> The FDA approved Becton, Dickinson and Company's line of prefilled generic injectables, which are designed to cut down on medication error and preparation time during injections. Release

> Zimmer Holdings launched an injectable pain relief gel to treat knee arthritis for patients who didn't respond to other steroids and pain relievers. Gel-One Hyaluronate benefits from the texture of its material, which is created via a cross-linking process. Story

> Researchers at the University of California have developed a leukemia treatment using a human antibody that targets and destroys the cells. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.